drugset / Trial / NCT05864105
PM8002 in Combination With Chemotherapy as First Line Therapy in Hepatocellular Carcinoma
NaSingle-groupOpen-labelTreatment
Summary
This is a multicenter, single-arm, open-label phase II study to evaluate the efficacy and safety of PM8002 in combination with chemotherapy in the first-line treatment of subjects with inoperable HCC.
Timeline
- Start
- 2022-04-22
- Primary completion
- 2025-07-24
- Completion
- 2025-07-24
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Pumitamig | Protein / enzyme biologic | 20 mg/kg | — |
| Background | Leucovorin | Small molecule | 200 mg/m2 | — |
| Background | Oxaliplatin | Small molecule | 85 mg/m2 | — |
| Background | fluorouracil | Small molecule | 400 mg/m2 | Intravenous |
| Background | fluorouracil | Small molecule | 600 mg/m2 | Intravenous |